Are you interested in reversing the state of T cell exhaustion?

If you are a biotech scientist interested in reversing or overcoming the state of T-cell exhaustion, this webinar will show you how advanced flow cytometry can be used to effectively evaluate immuno-oncology drugs using physiologically relevant assays.

Quantifying T cell exhaustion: An insight into BiTE antibodies and CAR-T cells for improved therapeutics will be hosted by DDW and presented by Sartorius. It will examine T cell exhaustion and how it is recognised as a major challenge in the development of immuno-oncology therapies.

Being able to predict how drugs will work in vivo is an important factor in their development and this webinar will show how in vitro assays can be used to do this. The end-to end solution for therapeutic drug interrogation outlined in this talk provides a significant advantage to the user by creating an environment for fast, accurate decision making, thus speeding up the drug discovery process.

T cells are fundamental in the coordination and execution of immune cell-mediated killing of infected or cancerous cells. Throughout the development of a T cell, variations in surface marker expression and cytokine release lead to important changes in function.

Following antigen recognition, cytotoxic effector T cells become activated, inducing target-cell killing capabilities. Repeated stimulation can lead to loss of function due to T cell exhaustion and ultimately cell death. Post antigen clearance, some effector T cells will transition into long-term memory T cells which retain survival and proliferation properties. These provide lasting immunity through their ability to rapidly expand when re-exposed to a specific antigen.

A growing number of immunotherapies, for example bispecific antibodies, checkpoint inhibitors and CAR-T cells, are being developed, targeting various stages in T cell activation and differentiation pathways. The goal of these therapeutics is to enhance the natural power of the immune system to eliminate diseases such as cancer. Detailed characterisation during the course of T cell development has the potential to offer greater insights leading to improved therapeutics.

Lauren Kelsey, a scientist in the iQue applications group, part of the European based BioAnalytics at Sartorius will discuss how the development of tumour-specific immunotherapies focuses on overcoming this exhausted phenotype of T cells to allow targeted killing of the tumour.

To listen to this free-to-attend webinar, which will take place on 22 October 2020 3:00 PM – 4:00 PM BST please sign up here (subject to approval).


Webinar overview

Date: 22 October 2020
Time: 3pm UK BST

Duration:  1 hour
Cost: Free-to-attend (participation subject to approval)

Click here to register for free.





Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free